News
Verrica Pharmaceuticals
VRCA · NASDAQ
$3.47+$0.03 (+0.87%)TodayMarket closed ·
Prev close $3.44
Latest news
- News
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
- Press releaseGlobe Newswire
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
- News
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
- Press releaseGlobe Newswire
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
- News
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
- Press releaseGlobe Newswire
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
- News
Earnings Scheduled For May 12, 2026
- Press releaseBusiness Wire
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
- Press releaseBusiness Wire
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
- Press releaseBusiness Wire
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- News
Earnings Scheduled For March 11, 2026
- News
Earnings Outlook For Verrica Pharmaceuticals
- NewsAvi Kapoor
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
- News
Verrica Pharmaceuticals Q3 Adj. EPS $0.13 Beats $(0.68) Estimate, Sales $14.344M Beat $5.843M Estimate
- Press releaseGlobe Newswire
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
- Press releaseBusiness Wire
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
- News
Verrica Pharmaceuticals Q2 Adj. EPS $0.25 Beats $(0.07) Estimate, Sales $12.702M Beat $4.367M Estimate
- News
Earnings Scheduled For August 12, 2025
- News
What to Expect from Verrica Pharmaceuticals's Earnings
- News
Earnings Outlook For Verrica Pharmaceuticals
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- NewsAvi Kapoor
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
- NewsAvi Kapoor
S&P 500 Gains 1%; Vimeo Shares Spike Higher
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
- Press releaseBusiness Wire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
- Press releasePRNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
- Press releaseBusiness Wire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
- NewsAvi Kapoor
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
- NewsAvi Kapoor
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
- NewsAvi Kapoor
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
- NewsAvi Kapoor
US Stocks Mixed; Inflation Rate Falls More Than Projected
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.